Beam Therapeutics Inc. (BEAM) stock
BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/304% below fair value
$22.83−1.20 (-4.99%)
Close on Nov 13, 2026Market cap $2.36BP/E –Yield –
Beam Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Beam Therapeutics's price to book ratio was 2.5× on Nov 11, 2026, against 2.7× a year earlier. Over the last 5 years it ranged from 1.4× to 6.5×, with a median of 2.8×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 2.5× | −0.4 |
| 2025 | Dec 31, 2025 | 2.9× | +0.3 |
| 2024 | Dec 31, 2024 | 2.6× | −0.2 |
| 2023 | Dec 29, 2023 | 2.8× | −1.1 |
| 2022 | Dec 30, 2022 | 3.9× | −2.5 |
| 2021 | Dec 31, 2021 | 6.3× | −14.3 |
| 2020 | Dec 31, 2020 | 20.6× | – |
See a number that looks wrong?